Small Animal Studies

摘要共享资源11：小动物研究(SAS-SR) 小动物研究共享资源(SAS-SR)由两部分组成：小动物影像 核心和动物肿瘤模型组件。这一组合资源可提供卓越的优质服务 为希望之城综合癌症中心(COHCCC)成员提供基础和转化型临床前研究 研究癌症生物学、抗癌药物开发和干细胞治疗开发。 SAS-SR的具体目标： 目的1.为动物实验的设计、实施和分析提供咨询。 目的2.促进发展新的动物模型和新的非侵入性活体成像 支持癌症研究的技术。 目标3.保持高质量进行动物研究所需的资源和专业知识 标准，并符合地方、州和国家的指导方针。 SAS-SR的小动物成像部分提供咨询、先进的成像设备、 成像服务，对COHCCC成员的实践培训，以及对礼宾和赠款准备的支持。 成像实验室目前的系统包括五个生物发光/荧光光学成像装置 (光谱仪器成像公司的LAGO/LAGO X/AMI HTX和PerkinElmer IVIS)，GNEXT PET/CT 仪器(SofieBiosciences)、7T MRI/PET(MRSolutions)和超声成像仪(Visualsonics VEVO)。 这些系统支持基于分子的成像，以允许监视细胞过程和非 治疗剂药代动力学和药效学的侵入性评估。动物肿瘤 SAS-SR的模型组件已经建立了多种癌症的患者来源的异种移植(PDX)模型 与COH教职员工合作，开发了下一代人性化小鼠模型，用于 癌症免疫治疗和体内药物代谢/毒性研究。PDX模型的开发支持 精确医学使研究人员能够评估肿瘤的生长和个体的治疗反应 病人。动物肿瘤模型部分还提供专门的药物递送服务，培训 VIVO程序，并支持方案准备和赠款开发。SAS-SR由Dr。 免疫学和血液学系教授兼主任胡红玉和副研究员吴军博士 比较医学研究教授。活动由高素质的人员提供支持， 维护和操作仪器。 2017-21年度按收入百分比划分的成员使用率：96.7总计(11.2 MCBC、33.4 DCT、26.6 CI、25.5 HM) 成员出版物：88，28，带影响因子&gt；10 支持的赠款总数：78(3个ACS、8个CIRM、8个DoD、4个LLS、46个NIH的33个NCI(32个R01、1个U01))

Abstract Shared Resource 11: Small Animal Studies (SAS-SR) The Small Animal Studies Shared Resource (SAS-SR) comprises two components: the Small Animal Imaging Core and the Animal Tumor Models component. This combined resource provides exceptional quality services for City of Hope Comprehensive Cancer Center (COHCCC) Members for basic and translational preclinical studies in cancer biology, anti-cancer drug development, and stem cell therapeutic development. Specific Aims for SAS-SR: Aim 1. Provide consultation for the design, performance, and analysis of animal experiments. Aim 2. Facilitate the development of new animal models and novel non-invasive in vivo imaging technology in support of cancer research. Aim 3. Maintain the resources and expertise necessary for conducting animal research with high quality standards and in compliance with local, state, and national guidelines. The Small Animal Imaging component of the SAS-SR provides consultation, advanced imaging equipment, imaging services, hands-on training for COHCCC Members, and support for protocol and grant preparation. Current systems in the Imaging Laboratory include five units for bioluminescence/fluorescence optical imaging (Lago/Lago X/Ami HTX from Spectral Instruments Imaging and a PerkinElmer IVIS), a GNEXT PET/CT instrument (SofieBiosciences), a 7T MRI/PET (MRsolutions), and ultrasound imager (VisualSonics VEVO). These systems support molecular-based imaging to allow for the monitoring of cellular processes and the non- invasive assessment of pharmacokinetics and pharmacodynamics of therapeutic agents. The Animal Tumor Models component of the SAS-SR has established patient-derived xenograft (PDX) models of multiple cancers in collaboration with COH faculty and has developed next-generation humanized mouse models for research in cancer immunotherapy and in vivo drug metabolism/toxicity studies. The development of PDX models supports precision medicine allowing investigators to evaluate tumor growth and therapeutic response for individual patients. The Animal Tumor Models component also provides specialized drug delivery services, training for in vivo procedures, and support for protocol preparation and grant development. The SAS-SR is co-directed by Dr. Anna Wu, Professor and Chair, Department of Immunology and Theranostics and by Dr. Jun Wu, an Associate Research Professor of Comparative Medicine. Activities are supported by highly qualified personnel that maintain and operate the instrumentation. Members Utilization by %Revenue 2017–21: 96.7 Total (11.2 MCBC, 33.4 DCT, 26.6 CI, 25.5 HM) Publications by Members: 88, 28 with Impact Factor >10 Grants Supported: 78 Total (3 ACS, 8 CIRM, 8 DoD, 4 LLS, 33 NCI of 46 NIH (32 R01, 1 U01))